Relmada Therapeutics Stock Price

0.60 (1.66%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Relmada Therapeutics Inc RLMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.60 1.66% 36.80 18:00:11
Close Price Low Price High Price Open Price Previous Close
36.80 36.20 37.585 36.20 36.20
Bid Price Ask Price Spread News
11.00 40.80 29.80 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,025 55,257 $ 36.85 $ 2,035,971 70,354 10.70 - 54.00
Last Trade Time Type Quantity Stock Price Currency
16:00:17 formt 704 $ 36.80 USD

Relmada Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 589.68M 16.02M 15.73M $ - $ - -2.98 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Relmada Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RLMD Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week39.5040.1834.8538.1582,586-2.70-6.84%
1 Month34.7340.8733.7237.5573,0162.075.96%
3 Months43.0345.5033.7239.1184,822-6.23-14.48%
6 Months30.8154.0029.1042.37134,8745.9919.44%
1 Year10.8554.0010.7039.51161,57025.95239.17%
3 Years10.8554.0010.7039.51161,57025.95239.17%
5 Years10.8554.0010.7039.51161,57025.95239.17%

Relmada Therapeutics Description

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of proven drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The product portfolio of the company includes d-Methadone, an N-methyl-D-aspartate receptor antagonist for treating depression and neuropathic pain; LevoCap ER, an abuse-resistant, the dosage form of the opioid analgesic levorphanol; BuTab an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Its lead product d-Methadone is an oral agent for the treatment of depression, pain, and other potential conditions affecting the brain functions.

Your Recent History
Relmada Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.